1. Home
  2. EDD vs ATYR Comparison

EDD vs ATYR Comparison

Compare EDD & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

EDD

Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

HOLD

Current Price

$5.57

Market Cap

345.5M

Sector

Finance

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.72

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDD
ATYR
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
345.5M
79.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
EDD
ATYR
Price
$5.57
$0.72
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$8.75
AVG Volume (30 Days)
254.3K
2.0M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
7.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$190,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18,728.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.22
$0.64
52 Week High
$4.95
$7.29

Technical Indicators

Market Signals
Indicator
EDD
ATYR
Relative Strength Index (RSI) 55.25 41.75
Support Level $5.41 $0.70
Resistance Level $5.55 $0.85
Average True Range (ATR) 0.06 0.05
MACD -0.01 0.01
Stochastic Oscillator 58.62 19.29

Price Performance

Historical Comparison
EDD
ATYR

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: